Yikes. That's pretty risky because even if AVXL doesn't release any news on Monday, the share price could still rocket higher if adu*** is rejected by the FDA.
In fact, I would expect ALL of the small biotech companies with pending AD drugs to rally fast and hard if adu*** is rejected. Conversely, I would expect BIIB to sell-off fast and hard since they no longer have a drug in the AD sphere.
News 
Market Data 
Discover 
